Displaying 49 - 60 of 85
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

Mirum: Meet the Experts in Cholestatic Liver Disease - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

Mirum: Meet the Experts in Cholestatic Liver Disease - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Cirrhosis & Complications
4

Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results - EASL Congress 2024

View
Cirrhosis & Complications
4

Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results - EASL Congress 2024

View
Cirrhosis & Complications
4

Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Displaying 49 - 60 of 85